New hope for lung scarring: HEC585 enters final testing phase
NCT ID NCT07082842
First seen Apr 25, 2026 · Last updated May 24, 2026 · Updated 9 times
Summary
This study tests a new tablet called HEC585 in about 472 adults aged 40-80 with idiopathic pulmonary fibrosis (IPF), a disease that scars the lungs and makes breathing hard. Participants are randomly assigned to receive HEC585, a placebo, or an existing drug (pirfenidone) to see if HEC585 can slow lung function decline over 52 weeks. The main goal is to measure changes in how much air the lungs can hold (FVC).
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IDIOPATHIC PULMONARY FIBROSIS (IPF) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
China-Japan Friendship Hospital
RECRUITINGBeijing, Beijing Municipality, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.